Companies: 10,795·Total market cap: $144.5T

Editas Medicine, Inc.

Editas Medicine, Inc.

EDITNASDAQHealthcare● Active

$2.66

$-0.05(-1.85%)

Market Cap$260414630

P/E Ratio—

52W High$4.537

52W Low$1.66

Avg Volume2.1M

Open$2.76

Beta2.10

股票排行：Biotechnology·Healthcare·查看全部市值排行 →

Editas Medicine, Inc.（EDIT）股票概览

关键指标与盈利、估值、营收、股息等标签页深链。

FMP · EDIT · 截至 Jun 8, 2026

关键指标

EPS (TTM)$-1.23Earnings history

PE Ratio (TTM)—PE Ratio deep dive

Revenue (TTM)$38.7MFull revenue history

Dividend Yield不分红Dividend history

Shares Outstanding88.7MShares outstanding history

Next EarningsAug 11, 2026Est.Earnings history

探索 Editas Medicine, Inc. 数据

分析师预测$5 · Buy

股息不分红

营收$40.5M+25.39%

盈利EPS $-1.80+37.50%

财务快照

FY 2025Revenue$40.5M▲ +25.39% YoY

202320242025

FY 2025Net Income-$160.1M▲ +32.49% YoY

202320242025

FY 2025EPS$-1.80▲ +37.50% YoY

202320242025

TTM:Revenue: $38.7MNet Income: -$109.0MEPS: $-1.23View income statement →

分析师评级与目标价

Buy25 位分析师

Strong Buy

0

Buy

14

Hold

9

Sell

2

Strong Sell

0

12-Month Price Target

$4.00Low

$2.66Current

$5.00Avg Target上涨空间 87.97%

$6.00High

合计: 25 · 买入占比: 56.0%

根据过去 3 个月内 25 位华尔街分析师，EDIT 共识评级为 Buy，12 个月平均目标价 $5.00 （较现价 $2.66 上涨空间 87.97%）。

竞争对手与同行

#TickerCompanyPriceChangeMkt Cap

Editas Medicine, Inc.

$2.66-1.85%$260.4M #2

Allogene Therapeutics, Inc.

$1.77-5.85%$431.7M #3

Atea Pharmaceuticals, Inc.

$4.43+3.06%$354.5M #4

Cabaletta Bio, Inc.

$3.20-1.62%$521.0M #5

Capricor Therapeutics, Inc.

$26.69-0.17%$1.2B #6

Immutep Limited

$0.37-1.09%$55.0M

股票表现

1D-1.66%

1W-4.82%

1M-14.31%

3M+33.25%

YTD+30.00%

1Y+38.08%

5Y-92.60%

关于 Editas Medicine, Inc.

CEOGilmore O'Neill

IPO DateFeb 3, 2016

Employees246

CountryUS

Websiteeditasmedicine.com

Editas Medicine, Inc. a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing plat…

Biotechnology HealthcareNASDAQUS

关于股票概览与关键数据

Editas Medicine, Inc.（EDIT）是 Biotechnology 行业的 Healthcare 类公司，于 Feb 3, 2016 在 NASDAQ 上市。截至最近交易日，EDIT 股价为 $2.66，市值约为 $260.9M。过去12个月累计回报 +38.08%，年初至今回报 +30.00%。

根据 25 位华尔街分析师，Editas Medicine, Inc. 股票共识评级为Buy，12个月平均目标价为 $5.00。2025 财年 Editas Medicine, Inc. 营收 $40.5M，净利润 -$160.1M。更多数据（营收历史、盈利、股息、市盈率）请使用上方标签页。

常见问题

截至最近一个交易日，Editas Medicine, Inc.（EDIT）股价为 $2.66，在 NASDAQ 上市，52周区间为 $1.66 – $4.54。

EDIT 最新股价EDIT quote todaylive ticker 实时行情

数据来源：Financial Modeling Prep最后更新：Jun 8, 2026本内容不构成投资建议